569 related articles for article (PubMed ID: 37313409)
1. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
3. A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang S; Chen W; Chi H; Wang W; Zhang W; Lin H; Yu Y
Aging (Albany NY); 2023 Oct; 15(19):10501-10523. PubMed ID: 37812215
[TBL] [Abstract][Full Text] [Related]
4. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
6. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
[TBL] [Abstract][Full Text] [Related]
7. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
Shen L; Li A; Cui J; Liu H; Zhang S
J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
9. Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.
Li C; Song W; Zhang J; Luo Y
Front Immunol; 2023; 14():1322147. PubMed ID: 38098487
[TBL] [Abstract][Full Text] [Related]
10. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.
Zhang D; Zhao F; Li J; Qin X; Li S; Niu R
Aging (Albany NY); 2023 Aug; 15(15):7811-7830. PubMed ID: 37561524
[TBL] [Abstract][Full Text] [Related]
11. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.
Shi X; Li Y; Pan S; Liu X; Ke Y; Guo W; Wang Y; Ruan Q; Zhang X; Ma H
Sci Rep; 2022 Feb; 12(1):1960. PubMed ID: 35121801
[TBL] [Abstract][Full Text] [Related]
13. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
Zhang Z; Wang J; Han W; Zhao L
BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
[TBL] [Abstract][Full Text] [Related]
14. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
Liu W; Wang M; Wang M; Liu M
Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
[TBL] [Abstract][Full Text] [Related]
15. Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis.
Shi M; Zhang H; Ma L; Wang X; Sun D; Feng Z
Front Immunol; 2024; 15():1352454. PubMed ID: 38515748
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.
Yao J; Duan L; Huang X; Liu J; Fan X; Xiao Z; Yan R; Liu H; An G; Hu B; Ge Y
Front Oncol; 2021; 11():769727. PubMed ID: 34926275
[TBL] [Abstract][Full Text] [Related]
17. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.
Zheng H; Liu H; Ge Y; Wang X
Cancer Cell Int; 2021 Oct; 21(1):552. PubMed ID: 34670584
[TBL] [Abstract][Full Text] [Related]
18. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract][Full Text] [Related]
19. Identification of m
Ma Y; Sun Y; Zhao X; Li J; Fu X; Gong T; Zhang X
Sci Rep; 2023 Sep; 13(1):14499. PubMed ID: 37666951
[TBL] [Abstract][Full Text] [Related]
20. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.
Ma C; Luo H
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102033. PubMed ID: 36265781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
